Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

2.
3.

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J.

J Infect Dis. 1998 Sep;178(3):651-61. Erratum in: J Infect Dis 1998 Nov;178(5):1553.

PMID:
9728532
4.

Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection.

Mahanty S, Gupta M, Paragas J, Bray M, Ahmed R, Rollin PE.

Virology. 2003 Aug 1;312(2):415-24.

6.

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J.

J Infect Dis. 1999 Feb;179 Suppl 1:S248-58.

PMID:
9988191
7.

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.

Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR.

Antiviral Res. 2003 Mar;58(1):47-56.

PMID:
12719006
8.

Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening.

Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST.

Virology. 2005 Feb 5;332(1):20-7.

9.

Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.

Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK.

J Comp Pathol. 2001 Nov;125(4):233-42.

PMID:
11798240
10.

Development of a broad-spectrum antiviral with activity against Ebola virus.

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q, Porter K, Goldblatt M, Bavari S.

Antiviral Res. 2009 Sep;83(3):245-51. doi: 10.1016/j.antiviral.2009.06.001. Epub 2009 Jun 10.

PMID:
19523489
11.

Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic.

Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ.

Arch Virol Suppl. 1996;11:115-34.

PMID:
8800793
12.

Protective efficacy of neutralizing antibodies against Ebola virus infection.

Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y.

Vaccine. 2007 Jan 22;25(6):993-9. Epub 2006 Oct 10.

PMID:
17055127
13.

Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection.

Swenson DL, Warfield KL, Warren TK, Lovejoy C, Hassinger JN, Ruthel G, Blouch RE, Moulton HM, Weller DD, Iversen PL, Bavari S.

Antimicrob Agents Chemother. 2009 May;53(5):2089-99. doi: 10.1128/AAC.00936-08. Epub 2009 Feb 17.

14.
15.

Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.

Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H.

J Infect Dis. 2007 Nov 15;196 Suppl 2:S404-12.

PMID:
17940977
16.

Development of treatment strategies to combat Ebola and Marburg viruses.

Paragas J, Geisbert TW.

Expert Rev Anti Infect Ther. 2006 Feb;4(1):67-76. Review.

PMID:
16441210
18.

Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target.

Montgomery JA, Clayton SJ, Thomas HJ, Shannon WM, Arnett G, Bodner AJ, Kion IK, Cantoni GL, Chiang PK.

J Med Chem. 1982 Jun;25(6):626-9.

PMID:
7097716
19.

Drug targets in infections with Ebola and Marburg viruses.

Gene OG, Julia BE, Vanessa MR, Victoria WJ, Thomas GW, Lisa HE.

Infect Disord Drug Targets. 2009 Apr;9(2):191-200. Review.

PMID:
19275706
20.

Progress towards the treatment of Ebola haemorrhagic fever.

Ströher U, Feldmann H.

Expert Opin Investig Drugs. 2006 Dec;15(12):1523-35. Review.

PMID:
17107278

Supplemental Content

Support Center